News | November 30, 2025
a2z wins FDA nod for groundbreaking abdomen-pelvis CT AI Triage system
Abdomen-pelvis CT is the nation’s highest-volume CT category
Abdomen-pelvis CT is the nation’s highest-volume CT category
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Subscribe To Our Newsletter & Stay Updated
